Supernus Q2 Revenue Jumps 32%, Raises Full-Year Guidance Amid Merger Announcement
SUPN sits 49% above its 52-week low of $32.83.
Summary
Supernus reported Q2 2026 revenue of $219.1M (+32% YoY) and raised full-year guidance, but a non-cash impairment charge led to a GAAP loss. The results coincide with the announcement of a merger with Indivior.
Key Events · Earnings and Guidance · SUPN
-
Q2 Revenue Surges 32%
Total revenues reached $219.1 million, up from $165.5 million a year ago, driven by 52% growth in combined sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO.
-
Full-Year Guidance Raised
Revenue guidance lifted to $860M-$890M (from $840M-$870M) and adjusted operating earnings to $150M-$180M (from $140M-$170M), reflecting confidence in growth products.
-
GAAP Loss on Impairment
A $54.9 million non-cash intangible asset impairment for APOKYN drove a GAAP operating loss of $58.0 million and a net loss of $58.4 million ($1.01 per share).
-
ONAPGO Regulatory Progress
Submission for a second ONAPGO supplier remains on track for Q3 2026, with potential FDA approval by mid-2027, supporting supply chain resilience.
Analysis · SUPN · Life Sciences
Supernus delivered a strong Q2 with total revenues up 32% to $219.1 million, driven by 52% growth in its four key products. The company raised its full-year 2026 revenue and adjusted operating earnings guidance, signaling confidence in sustained momentum. However, a $54.9 million non-cash impairment on APOKYN pushed GAAP results to a loss, and the guidance range for GAAP operating loss widened. The results land on the same day as the announcement of a merger of equals with Indivior, adding strategic complexity. Investors will weigh the strong commercial execution against the dilution and integration risks of the pending all-stock merger.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SUPN was trading at $49.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $32.83 to $59.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.